|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Aug 28, 2009. 5 OTHER
CHARGES
For the first half of 2009, included within cost of sales,
SG&A expenses, and R&D expenses were total other
charges of $40.6 million (2008: $5.6 million)
consisting of the following:
2009
During the first half of 2009, we incurred severance,
restructuring and asset impairment charges of $40.6 million
which were principally associated with the postponement of our
biologics manufacturing activities, the strategic redesign and
realignment of the R&D organisation within our
Biopharmaceuticals business, and reduction of related support
activities. These adjustments resulted in a reduction in our
global workforce of approximately 230 positions, or 14% of our
total workforce.
2008
During the first half of 2008, we incurred severance,
restructuring and other costs of $5.6 million arising
principally from the 2007 site consolidation in our
U.S. west coast operations and the restructuring of our
commercial infrastructure which resulted in the closure of the
San Diego facility and the expansion of our operations in
South San Francisco. The restructuring of our commercial
infrastructure was primarily a result of the approval of a
generic form of Maxipime and the anticipated approval of
a generic form of Azactam.
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Other
Charges
During 2007, we incurred severance, restructuring and other
costs of $3.8 million, $0.2 million included within
cost of sales and $3.6 million included within SG&A,
arising from the realignment of our resources to meet our
business structure at that time.
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
